Pyxis Oncology, Inc.
PYXS
$3.37
-$0.63-15.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -82.53% | -82.53% | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -82.53% | -82.53% | -100.00% | -- | -- |
| Cost of Revenue | -100.00% | -100.00% | -100.00% | -- | -- |
| Gross Profit | -82.00% | -82.00% | -100.00% | -- | -- |
| SG&A Expenses | -18.00% | -30.52% | -30.29% | -27.05% | -28.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.13% | 4.26% | 3.36% | 1.61% | -20.44% |
| Operating Income | -28.37% | -25.47% | -29.32% | 18.47% | 36.39% |
| Income Before Tax | -72.55% | -65.81% | -68.50% | -7.73% | 39.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.27% | -62.64% | -64.75% | -4.80% | 39.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.27% | -62.64% | -64.75% | -4.80% | 39.17% |
| EBIT | -28.37% | -25.47% | -29.32% | 18.47% | 36.39% |
| EBITDA | -31.38% | -27.51% | -31.38% | 20.26% | 38.61% |
| EPS Basic | -50.13% | -25.05% | -12.73% | 31.46% | 58.91% |
| Normalized Basic EPS | -20.43% | -0.29% | 9.42% | 47.91% | 58.90% |
| EPS Diluted | -50.13% | -25.05% | -12.73% | 31.46% | 58.91% |
| Normalized Diluted EPS | -20.43% | -0.29% | 9.42% | 47.91% | 58.90% |
| Average Basic Shares Outstanding | 13.73% | 23.95% | 38.76% | 46.50% | 44.78% |
| Average Diluted Shares Outstanding | 13.73% | 23.95% | 38.76% | 46.50% | 44.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |